Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice.

导出 LinkOut

翻译打印收藏纠错

作者： Yimin,Tu ^[1] ; Qing,Li ^[2] ; Yuanchen,Zhou ^[2] ; Zixiang,Ye ^[2] ; Chao,Wu ^[2] ; Enmin,Xie ^[1] ; Yike,Li ^[1] ; Peizhao,Li ^[2] ; Yaxin,Wu ^[2] ; Ziyu,Guo ^[2] ; Changan,Yu ^[3] ; Jingang,Zheng ^[1] ; Yanxiang,Gao ^[3]

作者单位： Department of Cardiology, China-Japan Friendship School of Clinical Medicine, Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. ^[1] Department of Cardiology, Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China. ^[2] Department of Cardiology, China-Japan Friendship Hospital, Beijing, China. ^[3]

关键词 coronary microvascular dysfunction diabetes empagliflozin pericytes sodium-glucose cotransporter 2 inhibitors

DOI 10.3389/fcvm.2022.995216

PMID 36588571

发布时间 2023-11-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in cardiovascular medicine

2022年9卷

995216页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice.

Frontiers in cardiovascular medicine

相似文献

Frontiers in cardiovascular medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice.

Frontiers in cardiovascular medicine

相似文献

Frontiers in cardiovascular medicine

相关期刊

检索历史清除